Suppr超能文献

BRCA 功能丧失,包括 BRCA1 基因甲基化,但不包括 BRCA 无关的同源重组缺陷,与高级别卵巢癌的铂类药物超敏反应相关。

BRCA loss of function including BRCA1 DNA-methylation, but not BRCA-unrelated homologous recombination deficiency, is associated with platinum hypersensitivity in high-grade ovarian cancer.

机构信息

Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria.

Institute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.

出版信息

Clin Epigenetics. 2024 Nov 27;16(1):171. doi: 10.1186/s13148-024-01781-0.

Abstract

BACKGROUND

In high-grade ovarian cancer (HGOC), determination of homologous recombination deficiency (HRD) status is commonly used in routine practice to predict response to platinum-based therapy or poly (ADP-ribose) polymerase inhibitors (PARPi). Here we tested the hypothesis that BRCA loss of function (LOF) due to epigenetic or genetic aberrations is a better predictor for the clinical outcome than HRD. One hundred thirty-one HGOC tissues were tested for BRCA DNA-methylation, BRCA mutations, HRD and BRCA1 mRNA expression, followed by a comprehensive survival analysis.

RESULTS

BRCA1-methylation was detected in 11% of the tumors, exclusively in BRCA1-wild-type (wt) HGOCs. BRCA1-methylated tumors (BRCA1-meth) had HRD-scores similar to those of BRCA-mutated (mut) tumors, and higher compared to unmethylated-BRCA-wt tumors (BRCA-wt-unmeth; P < 0.001). Platinum-refractory or -resistant HGOCs at first recurrence were all BRCA-unmeth cancers. Only one of the BRCA-mut cancers had a platinum-resistant recurrence. Thus, 99% of relapses in cancers with epigenetic or genetic BRCA-alterations were platinum-sensitive. Multivariate analysis confirmed BRCA-LOF as an independent predictor of progression-free survival (PFS) and overall survival (OS), whereas HRD-status had no predictive value for PFS and OS. Patients with BRCA-wt-unmeth cancers had the worst outcome compared to patients with cancers harboring epigenetic or genetic BRCA-alterations (PFS: P = 0.007; OS: P = 0.022). Most importantly, the BRCA-wt-unmeth subfraction of HRD-positive HGOCs exhibited the same poor survival as the entire HRD-negative cohort.

CONCLUSION

In HGOC BRCA mutational status together with BRCA1-methylation exhibit the best predictive power for favorable clinical outcome and thus high sensitivity to platinum-based therapy, whereas BRCA-unrelated HRD positivity was not associated with improved platinum sensitivity.

摘要

背景

在高级别卵巢癌(HGOC)中,同源重组缺陷(HRD)状态的确定通常用于常规实践,以预测对铂类治疗或聚(ADP-核糖)聚合酶抑制剂(PARPi)的反应。在这里,我们检验了这样一个假设,即由于表观遗传或遗传异常导致的 BRCA 功能丧失(LOF)比 HRD 更能预测临床结果。对 131 个 HGOC 组织进行了 BRCA 基因甲基化、BRCA 突变、HRD 和 BRCA1 mRNA 表达检测,随后进行了全面的生存分析。

结果

在 11%的肿瘤中检测到 BRCA1 甲基化,仅存在于 BRCA1 野生型(wt)HGOC 中。BRCA1 甲基化肿瘤(BRCA1-meth)的 HRD 评分与 BRCA 突变(mut)肿瘤相似,且高于未甲基化的 BRCA1-wt 肿瘤(BRCA-wt-unmeth;P<0.001)。首次复发时铂类耐药或铂类难治性 HGOC 均为 BRCA-unmeth 癌症。仅有一个 BRCA 突变癌症出现铂类耐药复发。因此,99%的具有表观遗传或遗传 BRCA 改变的癌症的复发是铂类敏感的。多变量分析证实 BRCA-LOF 是无进展生存期(PFS)和总生存期(OS)的独立预测因子,而 HRD 状态对 PFS 和 OS 没有预测价值。与携带表观遗传或遗传 BRCA 改变的癌症患者相比,BRCA-wt-unmeth 癌症患者的预后最差(PFS:P=0.007;OS:P=0.022)。最重要的是,HRD 阳性的 HGOC 中 BRCA-wt-unmeth 亚群与整个 HRD 阴性队列的生存情况相同差。

结论

在 HGOC 中,BRCA 突变状态与 BRCA1 甲基化一起,对临床结果具有最佳的预测能力,因此对铂类治疗高度敏感,而与 BRCA 无关的 HRD 阳性与提高铂类敏感性无关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f6d/11603837/19ea74bb396a/13148_2024_1781_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验